Clinical significance of serum tumor markers in patients with CKD 4/CKD 5

孙璐,卢照翾,卢方平
DOI: https://doi.org/10.3760/cma.j.cn115399-20220125-01005
2022-01-01
Abstract:Objective:To evaluate the serum concentrations of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) in patients with chronic kidney disease (CKD) in stage 4 and 5, and determine the relationship between these markers and renal function.Methods:We selected 29 patients with glomerular filtration rate (eGFR) < 30 ml/(min·1.73 m 2) as the case group and 23 patients with renal disease whose eGFR was greater than 90 ml/(min·1.73 m 2) as the control group, who were without renal replacement therapy and no malignant tumor hospitalized from January 2017 to July 2020. The concentrations of serum AFP, CEA and Cyfra21-1 and eGFR were collected, and their correlations between tumor markers and renal function were analyzed. Results:There were significant differences in the median serum concentration and the overall positive rate of Cyfra21-1 and CEA between the two groups ( P<0.05). There was no significant difference in the positive rate of AFP and the median serum concentration between the two groups. Spearman correlation analysis and Logistic regression analysis showed that the increase of Cyfra21-1 and CEA were related to the degree of renal function injury ( P<0.05). Conclusions:The increase of Cyfra21-1 and CEA in patients with CKD 4/CKD 5 was related to the degree of renal function damage.
What problem does this paper attempt to address?